Biogen Inc
XHAM:IDP

Watchlist Manager
Biogen Inc Logo
Biogen Inc
XHAM:IDP
Watchlist
Price: 148.35 EUR 1.85%
Market Cap: €21.6B

Operating Margin

28.5%
Current
Improving
by 1.8%
vs 3-y average of 26.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
28.5%
=
Operating Income
$2.9B
/
Revenue
$10.1B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
28.5%
=
Operating Income
€2.9B
/
Revenue
$10.1B

Peer Comparison

Country Company Market Cap Operating
Margin
US
Biogen Inc
NASDAQ:BIIB
25.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
166.3B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.9B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Higher than 89% of companies in the United States of America
Percentile
89th
Based on 14 112 companies
89th percentile
28.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Biogen Inc
Glance View

Biogen Inc. finds its roots in the cutting-edge world of biotechnology, where science meets the needs of patients battling complex neurological diseases. Founded in 1978 by a group of visionary scientists, including Nobel laureates, Biogen has evolved into a leader known primarily for its focus on neuroscience. Nestled in Cambridge, Massachusetts, the company operates with a singular goal—transforming the understanding and treatment of neurological disorders. The enterprise drives its mission through rigorous research and development (R&D), which forms the backbone of its operations. Biogen invests substantial resources in unveiling the mysteries of diseases such as multiple sclerosis (MS), Alzheimer's, and spinal muscular atrophy, striving to pioneer therapies that can profoundly improve patient outcomes. Biogen's revenue model is heavily contingent upon the successful commercialization of its R&D endeavors. The company primarily earns its revenue by developing and marketing prescription drugs that target neurological conditions. Signature products, such as Tecfidera, Tysabri, and Spinraza, have become mainstays in the management of multiple sclerosis and spinal muscular atrophy, respectively, delivering significant returns. By continually reinvesting in its drug pipeline, Biogen stays at the forefront of biopharmaceutical innovation, seeking to expand its portfolio and rigging favorable licensing deals and collaborations along the way. These elements ensure not just the sustenance but also the growth of its market presence, driving the company forward in a competitive and ever-evolving industry landscape.

IDP Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
28.5%
=
Operating Income
$2.9B
/
Revenue
$10.1B
What is Biogen Inc's current Operating Margin?

The current Operating Margin for Biogen Inc is 28.5%, which is above its 3-year median of 26.7%.

How has Operating Margin changed over time?

Over the last 3 years, Biogen Inc’s Operating Margin has increased from 27.6% to 28.5%. During this period, it reached a low of 22% on Mar 31, 2024 and a high of 32.3% on Mar 31, 2023.

Back to Top